Henry Castro

639 total citations
25 papers, 486 citations indexed

About

Henry Castro is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Henry Castro has authored 25 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Henry Castro's work include Hedgehog Signaling Pathway Studies (4 papers), CAR-T cell therapy research (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Henry Castro is often cited by papers focused on Hedgehog Signaling Pathway Studies (4 papers), CAR-T cell therapy research (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Henry Castro collaborates with scholars based in United States, United Kingdom and Germany. Henry Castro's co-authors include Joseph A. Bellanti, Aderbal Sabrá, Dalila Sellami, Jonathan Malka-Rais, Henriette Svarre Nielsen, Manisha Mone, Alexander Stratigos, Luc Dirix, Tingting Yi and Anne Lynn S. Chang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Henry Castro

23 papers receiving 465 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Henry Castro United States 10 189 155 114 106 77 25 486
Robert S. Stern United States 7 113 0.6× 123 0.8× 156 1.4× 539 5.1× 265 3.4× 8 773
Jun‐Kai Kao Taiwan 14 207 1.1× 68 0.4× 110 1.0× 50 0.5× 166 2.2× 32 575
Lilla Landeck Germany 18 93 0.5× 56 0.4× 41 0.4× 463 4.4× 176 2.3× 42 728
Rossella Gratton Italy 12 108 0.6× 17 0.1× 113 1.0× 157 1.5× 47 0.6× 22 406
Sven Schneider Austria 15 187 1.0× 225 1.5× 38 0.3× 26 0.2× 70 0.9× 52 700
Kristina Lee United States 12 144 0.8× 103 0.7× 132 1.2× 469 4.4× 522 6.8× 23 861
Masato Kakeda Japan 13 144 0.8× 47 0.3× 101 0.9× 316 3.0× 252 3.3× 22 686
Takaaki Hanafusa Japan 10 64 0.3× 27 0.2× 47 0.4× 134 1.3× 103 1.3× 26 440
K. Ishimoto Japan 17 132 0.7× 97 0.6× 66 0.6× 15 0.1× 115 1.5× 31 525
J-H. Saurat Switzerland 11 89 0.5× 59 0.4× 82 0.7× 298 2.8× 79 1.0× 16 503

Countries citing papers authored by Henry Castro

Since Specialization
Citations

This map shows the geographic impact of Henry Castro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry Castro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry Castro more than expected).

Fields of papers citing papers by Henry Castro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry Castro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry Castro. The network helps show where Henry Castro may publish in the future.

Co-authorship network of co-authors of Henry Castro

This figure shows the co-authorship network connecting the top 25 collaborators of Henry Castro. A scholar is included among the top collaborators of Henry Castro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry Castro. Henry Castro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Johnson, Melissa L., Anthony B. El-Khoueiry, Navid Hafez, et al.. (2021). Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 27(16). 4521–4530. 45 indexed citations
3.
Middleton, Mark R., Joseph J. Sacco, Kevin J. Harrington, et al.. (2021). 507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A539–A539. 1 indexed citations
4.
Johnson, Melissa L., Jordi Rodón, Nehal J. Lakhani, et al.. (2021). P01.06 CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients With Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase. Journal of Thoracic Oncology. 16(3). S238–S238. 3 indexed citations
5.
Luke, Jason J., Michael R. Migden, Wanxing Chai‐Ho, et al.. (2021). 550 ARTACUS: An open-label, multicenter, phase 1b/2 study of RP1 in solid organ transplant recipients with advanced cutaneous malignancies. Regular and Young Investigator Award Abstracts. A580–A580.
6.
Xu, Rui‐Hua, Hendrik‐Tobias Arkenau, Yung‐Jue Bang, et al.. (2020). Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.. Journal of Clinical Oncology. 38(4_suppl). TPS458–TPS458. 9 indexed citations
7.
8.
Budha, Nageshwar, et al.. (2019). Tislelizumab exposure-response analyses of efficacy and safety in patients with advanced tumors. Annals of Oncology. 30. v182–v183. 1 indexed citations
9.
Lear, John T., Michael R. Migden, Karl D. Lewis, et al.. (2017). Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study. Journal of the European Academy of Dermatology and Venereology. 32(3). 372–381. 137 indexed citations
10.
Horsmans, Yves, Oren Shibolet, Michelle Quinlan, et al.. (2017). Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study. Clinical Pharmacokinetics. 57(3). 345–354. 15 indexed citations
11.
Lear, John T., Ralf Gutzmer, Michael R. Migden, et al.. (2016). Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: results of the BOLT 30-month analysis. Melanoma Research. 1 indexed citations
12.
Dummer, Reinhard, Michael R. Migden, Alexander Guminski, et al.. (2016). Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.. Journal of Clinical Oncology. 34(15_suppl). 9538–9538. 2 indexed citations
13.
Quinlan, Michelle, Kelli Glenn, Hildegard Boss, et al.. (2016). Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers. British Journal of Clinical Pharmacology. 82(4). 1022–1029. 14 indexed citations
14.
Hamilton, Erika, Kimberly Blackwell, Amy Hobeika, et al.. (2012). Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion. Journal of Translational Medicine. 10(1). 28–28. 78 indexed citations
15.
Rodríguez-Villamizar, Laura Andrea, et al.. (2010). Prevalencia de síntomas respiratorios indicativos de asma y asociación con contaminación atmosférica en preescolares de Bucaramanga, Colombia. Biomédica. 30(1). 15–15. 10 indexed citations
16.
Caballero, M. Rosario, et al.. (2006). Recurrent infections and joint pain.. PubMed. 27(2). 164–71. 2 indexed citations
17.
Castro, Henry, Jonathan Malka-Rais, & Joseph A. Bellanti. (2005). Current epidemiology of asthma: emerging patterns of asthma.. PubMed. 26(2). 79–82. 6 indexed citations
18.
Bellanti, Joseph A., et al.. (2005). Are attention deficit hyperactivity disorder and chronic fatigue syndrome allergy related? what is fibromyalgia?. PubMed. 26(1). 19–28. 13 indexed citations
19.
Bellanti, Joseph A., et al.. (2003). Developmental immunology: clinical application to allergy-immunology. Annals of Allergy Asthma & Immunology. 90(6). 2–6. 21 indexed citations
20.
Sabrá, Aderbal, et al.. (2003). IgE and non-IgE food allergy. Annals of Allergy Asthma & Immunology. 90(6). 71–76. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert S. Stern Breakdown of academic impact, for papers by Jun‐Kai Kao Breakdown of academic impact, for papers by Lilla Landeck Breakdown of academic impact, for papers by Rossella Gratton Breakdown of academic impact, for papers by Sven Schneider Breakdown of academic impact, for papers by Kristina Lee Breakdown of academic impact, for papers by Masato Kakeda Breakdown of academic impact, for papers by Takaaki Hanafusa Breakdown of academic impact, for papers by K. Ishimoto Breakdown of academic impact, for papers by J-H. Saurat
Rankless by CCL
2026